|Table of Contents|

The value of Q-T interval dispersion combined with troponin I in the early diagnosis of cardiac toxicity induced by anthracycline c-hemotherapy in breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
71-74
Research Field:
Publishing date:

Info

Title:
The value of Q-T interval dispersion combined with troponin I in the early diagnosis of cardiac toxicity induced by anthracycline c-hemotherapy in breast cancer
Author(s):
CHANG Qinglong1; CUI Pingping1; WANG Huihua1; HAN Pei1; YUAN Yangyang2
1.Department of Breast Surgery;2.Research Center,the Third Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450000,China.
Keywords:
Q-T interval dispersion; breast cancer; anthracycline; chemotherapy; cardiotoxicity
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.01.012
Abstract:
Objective:To investigate the value of Q-T interval dispersion(QTd) combined with troponin I(cTnI) in the early detection of cardiotoxicity induced by anthracyclines.Methods:The clinical data of 97 patients with breast cancer who received anthracycline chemotherapy in our hospital from January 2019 to June 2020 were retrospectively analyzed.The patients were divided into observation group(cardiotoxicity group) and control group(non-cardiotoxicity group) according to the reduced range of left ventricular ejection fraction(LVEF) and symptoms of congestive heart failure as the reference criteria.The levels of QTd and cTnI were statistically analyzed,and the data were processed by SPSS 25.0 analysis software.Results:Cardiotoxicity occurred in 18 of the 97 patients enrolled,with an incidence of 18.6%.Before chemotherapy,there were no statistically significant differences in baseline QTd and cTnI levels between the control group and the observation group(P＞0.05).QTd and cTnI levels after each chemotherapy cycle were significantly higher than the baseline level(P＜0.05).The levels of QTd and cTnI in observation group were significantly higher than those in control group during the same chemotherapy cycle(P＜0.05).The area under ROC curve(AUC) of QTd and cTnI were 0.877 and 0.871,respectively.The sensitivity and specificity were 85.4%,82.6% and 96.5%,93.4%,respectively.The AUC of combined application was 0.876,the sensitivity and specificity were 84.0% and 97.3%,respectively.Conclusion:Both QTd and cTnI detection can be used as one of the prospective methods for noninvasive evaluation of cardiotoxicity induced by anthracycline.The combined application of QTd and cTnI has higher diagnostic value.

References:

[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[2］FITZMAURICE C,DICKER D,PAIN A,et al.Global burden of disease cancer collaboration,the global burden of cancer 2013［J］. JAMA Oncol,2015,1(4):505-527.
[3］KAUFMANN M,VON MINCKWITZ G,RODY A,et al.Preoperative(neoadjuvant) systemic treatment of breast cancer ［J］.Breast,2005,14(6):576-581.
[4］KAUFMANN M,HORTOBAGYI GN,GOLDHIRSCH A,et al.Recommendations from an internationalexpert panel on the use of neoadjuvant(primary) systemic treatment of operable breast cancer:An update［J］.Clin Oncol,2006,24(12):1940-1949.
[5］张萌萌，洛菲.蒽环类药物治疗乳腺癌的心血管风险及对策［J］.肿瘤研究与临床，2018，30(3)：173. ZHANG MM,LUO F.Cardiovascular risk ofbreast cancer treated with anthracyclines and countermeasures［J］.Cancer Research and Clinic,2018,30(3):173.
[6］SURACHETPONG SD,TEEWASUTRAKUL P,RUNGSIPI-PAT A.Serial measurements of cardiac tropon-in I(cTnI) in dogs treated with doxorubicin［J］.Jpn J Vet Res,2016,64(4):221-233.
[7］中国临床肿瘤学会，中华医学会血液学分会.蒽环类药物心脏毒性防治指南（2013年版）［J］.临床肿瘤学杂志，2013，18(10)：925-934. Chinese Society of Clinical Oncology,Hematology Branch of Chinese Medical Association.Anthracycline cardiotoxicity guidelines(2013 Edition)［J］.Chinese Clinical Oncology,2013,18(10):925-934.
[8］MARTINS-TEIXEIRA MB,CARVALHO I.Antitumour anthracyclines:Progress and perspectives［J］.Chem Med Chem,2020,15(11):933-948.
[9］CVETKOVI' C RS,SCOTT LJ.Dexrazoxane:A review of its use for cardioprotection during ant-hracycline chemotherapy［J］.Drugs,2005,65(7):1005-1024.
[10］MINOTTI G,MENNA P,SALVATORELLI E,et al.Anthracyclines:molecular advances and pha-rmacologic developments in antitumor activity and cardiotoxicity［J］.Pharmacol Rev,2004,56(2):185-229.
[11］CAPPETTA D,DE ANGELIS A,SAPIO L,et al.Oxidative stress and cellular response to doxorubicin:A common factor in the complex milieu of anthracycline cardiotoxicity［J］.Oxidative Medicine and Cellular Longevity,2017,2017:1521020.
[12］冯保华，王俊生，李保中，等．右丙亚胺对表阿霉素辅助化疗时的心脏保护作用及其机制分析［J］.现代肿瘤医学，2017，25(23)：3776-3779. FENG BH,WANG JS，LI BZ，et al.Anal-ysis of cardioprotective role of adjuvant che-motherapy and its mechanism of dexrazoxa-ne(DEX) on epirubicin(EPI)［J］.Modern Oncology,2017,25(23):3776-3779．
[13］LIPSHULTZ SE,LIPSITZ SR,SALLAN SE,et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia［J］.J Clin Oncol,2005,23(12):2629-2636.
[14］VAN DALEN EC,CAMN HN,DICKINSNHO,et al.Cardioprotective interventions for cancer patients receiving anthracyclines［J］.Cochrane Database Syst Rev,2011,6(2):CD003917.
[15］BOVELLI D,PLATANIOTIS G,ROILA F.Cardiotoxicity of chemotherapeutic agents and radiotherapyrelated heartdisease:ESMO clinical practice guidelines［J］.Annals of Oncology,2010,21(Suppl 5):277-282.
[16］薛成，王曦晖，付娆．血清cTnI联合BNP检测在乳腺癌化疗相关心脏毒性早期预测中的应用价值［J］．现代肿瘤医学，2021，29(08)：1339-1343. XUE C,WANG XH,FU R.Application val-ue of serum cTnI combined with BNP dete-ction in early prediction of chemotherapy －related cardiotoxicity in breast cancer［J］.Modern Oncology,2021,29(08):1339-1343.
[17］陈立凡，陈科奇，吴子平．QT间期离散度联合心脏超声对酒精依赖患者潜在心脏事件的评价作用分析［J］.中国医学工程，2021，29(05)：27-30. CHEN LF,CHEN KQ,WU ZP.Evaluation of QT interval dispersion combined with ca-rdiac ultrasound for potential cardiac events in alcohol-dependent patients［J］.China Medical Engineering,2021,29(05):27-30.

Memo

Memo:
-
Last Update: 2022-11-30